Retraction: Enhanced Anti-Tumor Effect of Zoledronic Acid Combined with Temozolomide against Human Malignant Glioma Cell Expressing O6-Methylguanine DNA Methyltransferase (PLoS ONE (2014) 9:8 (e104538) DOI: 10.1371/journal.pone.0104538);Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Fukai, Junya ^a,b   Koizumi, Fumiaki ^b   Nakao, Naoyuki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN KINASE B; RAS PROTEIN; TEMOZOLOMIDE; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DACARBAZINE; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DIPHOSPHONATES; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IMIDAZOLES; MICE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RAS PROTEINS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905843043     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0268315     Document Type: Erratum

References (29)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol 10: 459-466.
3. Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. J Clin Oncol 25: 4127-4136. (Pubitemid 47492957)
4. Roos WP, Batista LFZ, Naumann SC, Wick W, Weller M, et al. (2007) Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26: 186-197. (Pubitemid 46095730)
5. Knizhnik AV, Roos WP, Nikolova T, Quiros S, Tomaszowski KH, et al. (2013) Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One 8: e55665. doi: 10.1371/journal.pone.0055665.
6. Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, et al. (2013) Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PLoS One 8: e62351. doi:10.1371/journal.pone.0062351.
7. Branch P, Aquilina G, Bignami M, Karran P (1993) Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362: 652-654. (Pubitemid 23109278)
8. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, et al. (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16: 3851-3857. (Pubitemid 29001538)
9. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, et al. (2008) Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. J Clin Oncol 26: 4189-4199.
10. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Engl J Med 352: 997-1003. (Pubitemid 40349502)
11. Spiegl-Kreinecker S, Pirker C, Filipits M, Lötsch D, Buchroithner J, et al. (2010) O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro-Oncol 12: 28-36.
12. Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Philippe Clézardin. (2007) Bisphosphonates in cancer therapy. Cancer Lett 257: 16-35. (Pubitemid 47464698)
13. Fukai J, Yokote H, Yamanaka R, Arao T, Nishio K, et al. (2008) EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line. Mol Cancer Ther 7: 2768-2778.
14. Fukai J, Nishio K, Itakura T, Koizumi F (2008) Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. Cancer Sci 99: 2062-9.
15. Kanzawa F, Nishio K, Fukuoka K, Fukuda M, Kunimoto T, et al. (1997) Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3. Int J Cancer 71: 311-9. (Pubitemid 27224289)
16. Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, et al. (2005) Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47: 31-39. (Pubitemid 39643239)
17. Fernandes-Alnemri T, Litwack G, Alnemri ES (1994) CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269: 30761-30764. (Pubitemid 24377553)
18. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, et al. (1998) Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 273: 33533-33539. (Pubitemid 29005737)
19. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO (2005) Akt Activation Suppresses Chk2-Mediated, Methylating Agent-Induced G2 Arrest and Protects from Temozolomide-Induced Mitotic Catastrophe and Cellular Senescence. Cancer Res 65: 4861-4869. (Pubitemid 40740825)
20. Momota H, Nerio E, Holland EC (2005) Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 65: 7429-7435. (Pubitemid 41161277)
21. Patra SK (2008) Ras regulation of DNA-methylation and cancer. Exp Cell Res 314: 1193-1201.
22. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S, Wesseling P (2007) RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 114: 121-133. (Pubitemid 47103523)
23. The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
24. Senaratne SG, Mansi JL, Colston KW (2002) The bisphosphonate zoledronic acid impairs Ras membrane localization and induces cytochrome c release in breast cancer cells. Br J Cancer 87: 1479-1486. (Pubitemid 34548073)
25. Hirose Y, Berger S, Pieper RO (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide treated human glioblastoma cells. Cancer Res 61: 1957-1963. (Pubitemid 32692013)
26. Kuroda J, Kimura S, Segawa H, Sato K, Matsumoto S, et al. (2004) p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. Cancer Sci 95: 186-192. (Pubitemid 38404322)
27. Bryant NL, Suarez-Cuervo C, Gillespie GY, Markert JM, Nabors LB, et al. (2009) Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma. Neuro-Oncology 11: 357-367.
28. Nakazawa T, Nakamura M, Park YS, Motoyama Y, Hironaka Y, et al. (2014) Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma. J Neurooncol 116: 31-39.
29. Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, et al. (2008) Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 36: 2043-2049.